NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Mounjaro will soon be available on the NHS across the UK but it's important patients avoid the dangerous 'golden dose' trend ...

A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

The benefits from 2 new Alzheimer’s treatments remain too small to justify the additional cost to the NHS, an independent NICE c ...